Regulatory effects of eotaxin, eotaxin-2, and eotaxin-3 on eosinophil degranulation and superoxide anion generation.
Eosinophilic leukocytes have been implicated as primary effector cells in inflammatory and allergic diseases. When activated by cytokines, human eosinophils secrete and produce a variety of proinflammatory or tissue damaging substances. Although well known for their chemoattractant effects, little is known about the precise contribution of the eosinophil-selective chemokines, eotaxin, eotaxin-2, and eotaxin-3 to the effector functions of eosinophils. This forms the central focus of these investigations for which clone 15-HL-60 human eosinophilic cells were used as the in vitro model. Investigation results suggest that all three subtypes of eotaxin directly stimulate eosinophil superoxide anion generation that is inhibited by neutralizing eotaxin antibody or pretreatment of cells with the receptor antibody anti-CCR3. Pretreatment or co-treatment with each of the eotaxins augmented phorbol myristate-induced superoxide generation. Concentration-dependent degranulation of eosinophil peroxidase was noted for all three chemokines, and potentiation of calcium ionophore-induced degranulation was observed with eotaxin pretreatments. Results of interleukin-5 pretreatment studies suggest that the eotaxin chemokines may act cooperatively to enhance effector functions of eosinophils. Collectively, the present studies have advanced knowledge of the eotaxin family of chemokines to include eosinophil priming and modulation of eosinophil activation and secretion effector functions.
Badewa
A P
AP
Florida A & M University, College of Pharmacy and Pharmaceutical Sciences, Tallahassee, Florida 32307, USA.
Hudson
C E
CE
Heiman
A S
AS
D000001:Calcimycin / Q000494:pharmacology; D054413:Chemokine CCL11; D054423:Chemokine CCL24; D000075906:Chemokine CCL26; D019742:Chemokines, CC / Q000494:pharmacology*; D003594:Cytoplasmic Granules / Q000378:metabolism*; D047209:Eosinophil Peroxidase; D004804:Eosinophils / Q000187:drug effects* / Q000378:metabolism; D018922:HL-60 Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D015848:Interleukin-5 / Q000494:pharmacology; D007476:Ionophores / Q000494:pharmacology; D010544:Peroxidases / Q000378:metabolism; D054397:Receptors, CCR3; D019707:Receptors, Chemokine / Q000187:drug effects* / Q000502:physiology; D011994:Recombinant Proteins / Q000494:pharmacology; D013481:Superoxides / Q000378:metabolism*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
C515456:CCL11 protein, human; C515484:CCL24 protein, human; C120429:CCL26 protein, human; C515350:CCR3 protein, human; D054413:Chemokine CCL11; D054423:Chemokine CCL24; D000075906:Chemokine CCL26; D019742:Chemokines, CC; D015848:Interleukin-5; D007476:Ionophores; D054397:Receptors, CCR3; D019707:Receptors, Chemokine; D011994:Recombinant Proteins; D013481:Superoxides; D000001:Calcimycin; D047209:Eosinophil Peroxidase; D010544:Peroxidases; D013755:Tetradecanoylphorbol Acetate